| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5539 | 2021 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1743 | 2020 |
| Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen, L Fairlie, ... New England Journal of Medicine 384 (20), 1885-1898, 2021 | 1411 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1388 | 2021 |
| Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection S Feng, DJ Phillips, T White, H Sayal, PK Aley, S Bibi, C Dold, M Fuskova, ... Nature medicine 27 (11), 2032-2040, 2021 | 1116 | 2021 |
| History of oncolytic viruses: genesis to genetic engineering E Kelly, SJ Russell Molecular therapy 15 (4), 651-659, 2007 | 961 | 2007 |
| Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19 MJ Levin, A Ustianowski, S De Wit, O Launay, M Avila, A Templeton, ... New England Journal of Medicine 386 (23), 2188-2200, 2022 | 686 | 2022 |
| Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine AR Falsey, ME Sobieszczyk, I Hirsch, S Sproule, ML Robb, L Corey, ... New England Journal of Medicine 385 (25), 2348-2360, 2021 | 657 | 2021 |
| Engineering microRNA responsiveness to decrease virus pathogenicity EJ Kelly, EM Hadac, S Greiner, SJ Russell Nature medicine 14 (11), 1278-1283, 2008 | 291 | 2008 |
| The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans YM Loo, PM McTamney, RH Arends, ME Abram, AA Aksyuk, S Diallo, ... Science translational medicine 14 (635), eabl8124, 2022 | 204 | 2022 |
| Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting EJ Kelly, R Nace, GN Barber, SJ Russell Journal of virology 84 (3), 1550-1562, 2010 | 149 | 2010 |
| Nirsevimab for prevention of RSV in term and late-preterm infants WJ Muller, SA Madhi, B Seoane Nunez, M Baca Cots, M Bosheva, ... New England Journal of Medicine 388 (16), 1533-1534, 2023 | 145 | 2023 |
| MicroRNAs and the regulation of vector tropism EJ Kelly, SJ Russell Molecular Therapy 17 (3), 409-416, 2009 | 121 | 2009 |
| Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences Á O’Toole, OG Pybus, ME Abram, EJ Kelly, A Rambaut BMC genomics 23 (1), 121, 2022 | 104 | 2022 |
| Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B. 1.351 variant in South Africa SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen, L Fairlie, ... MedRxiv, 2021.02. 10.21251247, 2021 | 104 | 2021 |
| Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial M Madhavan, AJ Ritchie, J Aboagye, D Jenkin, S Provstgaad-Morys, ... EBioMedicine 85, 2022 | 91 | 2022 |
| AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire PA Swanson, M Padilla, W Hoyland, K McGlinchey, PA Fields, S Bibi, ... Science translational medicine 13 (620), eabj7211, 2021 | 84 | 2021 |
| MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference EJ Kelly, EM Hadac, BR Cullen, SJ Russell PLoS pathogens 6 (3), e1000820, 2010 | 66 | 2010 |
| Oncolytic VSV primes differential responses to immuno-oncology therapy NM Durham, K Mulgrew, K McGlinchey, NR Monks, H Ji, R Herbst, ... Molecular Therapy 25 (8), 1917-1932, 2017 | 62 | 2017 |
| Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data D Wilkins, AC Langedijk, RJ Lebbink, C Morehouse, ME Abram, B Ahani, ... The Lancet Infectious Diseases 23 (7), 856-866, 2023 | 38 | 2023 |
